No Data
No Data
The Market Doesn't Like What It Sees From BeiGene, Ltd.'s (NASDAQ:BGNE) Revenues Yet
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Markets Sluggishly Move to Year-End
BeiGene Gains FDA Nod for TEVIMBRA, Marking Key Progress in Oncology Treatments
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemotherapy
BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50